Oncolytic Virus Cancer Therapy Market Set for Rapid Growth Through 2036

Technological progress in genetic engineering has enabled researchers to modify viral platforms to improve tumor selectivity, immune activation, and therapeutic payload delivery. Current clinical development includes adenoviruses, herpes simplex viruses, vaccinia viruses, reoviruses, measles viruses, Newcastle disease viruses, picornaviruses, Maraba viruses, vesicular stomatitis viruses, and other platforms.

The clinical pipeline includes candidates such as Cretostimogene grenadenorepvec, CAN-2409, AdAPT-001, LOAd703, RP1, RP2, VG 161, BS001, Olvi-Vec, CF33, BT-001, TG6050, and Pelareorep.

Increasing clinical trial activity across melanoma, bladder cancer, glioblastoma, ovarian cancer, pancreatic cancer, biliary tract cancer, and other solid tumors is expected to strengthen the commercial potential of this therapeutic class.

Discover real-time oncolytic virus analysis @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Competitive Landscape of Oncolytic Virus Cancer Therapy

The competitive landscape is characterized by multiple biotechnology and pharmaceutical companies advancing investigational therapies across different cancer indications. Key developers include CG Oncology, Candel Therapeutics, EpicentRx, Lokon Pharma, Replimune, Virogin Biotech, Binhui Bio, Genelux, Imugene, BioInvent, Transgene, and Oncolytics Biotech, among others.

Genelux’s Olvi-Vec is a genetically modified vaccinia virus being investigated across several cancer types. Its development strategy focuses on direct tumor-cell destruction, activation of tumor-specific immune responses, and modification of the tumor microenvironment.

CG Oncology’s cretostimogene grenadenorepvec is an investigational intravesical oncolytic immunotherapy being studied in non-muscle-invasive bladder cancer. The candidate has been evaluated in Phase III programs targeting different patient populations with bladder cancer.

Another example is BT-001, developed through collaboration between BioInvent and Transgene. The engineered oncolytic virus is designed to deliver an anti-CTLA-4 antibody directly within tumors and is being investigated in combination with pembrolizumab.

Recent Developments Shaping the Market

The oncolytic virus cancer therapy landscape has witnessed several notable developments in 2026. In August 2026, Replimune announced that the U.S. FDA granted accelerated approval to TUDRIQEVTM (vusolimogene oderparepvec-wtpg), formerly RP1, in combination with nivolumab for certain adults with unresectable advanced cutaneous melanoma following progression after an anti-PD-1-based regimen.

In July 2026, UroGen Pharma announced FDA clearance of its IND application for UGN-501, supporting plans for a Phase I clinical trial in non-muscle-invasive bladder cancer.